Table 3.
NOWS severity outcomes by the SSRI/SNIR exposure.
| NOWS severity outcomes | MOUD (n = 121) N (%) |
MOUD + SRI (n = 27) N (%) |
Unadjusted P | Adjusted Pa |
|---|---|---|---|---|
| NOWS requiring pharmacologic treatmentb | 46 (38.0) | 16 (59.3) | 0.053 | 0.01 |
| Morphine | 29 (24.0) | 12 (44.4) | – | – |
| Methadone | 25 (20.7) | 5 (18.5) | – | – |
| Median (Q1, Q3) | Median (Q1, Q3) | |||
| Duration of hospitalization in days | 6 (5, 18) | 11 (5, 20.5) | 0.16 | 0.02 |
| Duration of treatment in days (all infants) | 0 (0, 9) | 6 (0, 11) | 0.26 | 0.02 |
| Duration of treatment in days (infants who received pharmacologic treatment) | 12 (9, 18) | 10.5 (6, 14.5) | 0.66 | 0.20 |
a
Adjusted for the type of maternal use of MOUD, hydroxyzine, heroin/misuse of opioid analgesics, benzodiazepines/sedatives, alcohol use, tobacco, marijuana.
b
Categories are not mutually exclusive as nine infants (eight in MOUD and one in MOUD + SRI groups) were treated with both morphine and methadone during the hospitalization).